- contract manufacturing
A copy of the company’s Form 10-K, including the company’s completed audited financial statements, for the year ended December 31, 2013, filed with the Securities and Exchange Commission, is available without charge, upon written request to Investor Relations, Emergent BioSolutions Inc., Suite 400, Rockville, MD 20850.
|Webcasts & Presentations|
|Receive Email Alerts|
|Sign up to receive Email alerts whenever Emergent BioSolutions Inc. posts new information to the site. Just enter your Email address and click Submit.|
|Safe Harbor Statement|
|The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our financial guidance, and any other statements containing the words “believes”, “expects”, “anticipates”, "intends", “plans”, "forecasts", “estimates”, “may”, “will”, “would” and similar expressions, are forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Investors are, therefore, cautioned not to place undue reliance on any forward-looking statement. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax procurement; our ability to successfully integrate Cangene and realize the potential benefits of the transaction; our ability to successfully integrate the recent acquisition of the HPPD business and realize the benefits of the HPPD transaction; our ability to obtain new BioThrax sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax; availability of funding for our U.S. government grants and contracts; our ability to identify and acquire or in-license products or late-stage product candidates that satisfy our selection criteria; whether anticipated synergies and benefits from an acquisition or in-license are realized within expected time periods or at all; our ability to enter into selective collaboration arrangements; our ability to expand our manufacturing facilities and capabilities; our ability to meet operating and financial restrictions placed on us and our subsidiaries that are contained in our senior credit facility; the rate and degree of market acceptance and clinical utility of our products; the success of our ongoing and planned development programs; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; and our commercialization, marketing and manufacturing capabilities and strategy. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements. The company disclaims any intention or obligation to update any forward-looking statements contained in or directly accessible from documents on this website.|
|Quotes delayed at least 15 minutes. Market data provided by Interactive Data.|
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.